Communiqués Gimv NV

Actions

GIMB

BE0003699130

Gestion des placements et exploitants de fonds

Marché Fermé - Euronext Bruxelles 17:55:00 04/09/2026			Varia. 5j.	Varia. 1 janv.
44,80 ^EUR	0,00%		+0,79%	+0,34%

03/09	Gimv NV publie ses résultats pour le semestre clos le 30 juin 2026	CI
03/09	Gimv bien orienté après sa publication semestrielle

Communiqués

03/09	Gimv : Excellent portfolio performance leads to a 7.5% increase in Net Asset Value to EUR 57.2 per share	PU
11/08	Gimv : Metis Group has reached an agreement with EPAC’s existing shareholders to acquire a majority stake in the company.	PU
11/08	Gimv : Spineart Announces FDA Approval of BAGUERA® C Cervical Disc	PU
22/07	Gimv : Kinaset Therapeutics Announces First Patient Dosed in Phase 2b PANAIRAMA Trial of frevecitinib (KN-002) in Patients with Severe Asthma	PU
30/06	Gimv : sells its stake in AlpenBlu Clinics (formerly Les Psy Réunis), a Swiss provider of outpatient mental healthcare, to Impact Healthcare.	PU
30/06	Gimv : cède sa participation dans AlpenBlu Clinics (précédemment Les Psy Réunis), acteur suisse des soins ambulatoires en santé mentale, à Impact Healthcare	PU
25/06	Gimv : signs an agreement to acquire Groupe Cap Vert, France’s leading multi-specialist provider of tree and vegetation critical management services, from Ambienta.	PU
25/06	Gimv : signe un accord en vue d’acquérir le Groupe Cap Vert, leader français multi-spécialiste des services de gestion du patrimoine arboré et végétal, auprès d’Ambienta	PU
23/06	Gimv : Cegeka acquires cybersecurity specialist 3Point	PU
02/06	Gimv : Quality Guard strengthens its European position with the acquisition of Kooklin.	PU
02/06	Gimv : Quality Guard renforce sa position en Europe avec l’acquisition de Kooklin.	PU
27/05	Gimv : Report ordinary & special general meeting of May 27, 2026	PU
27/05	Gimv : Minutes (260527 NTL AV %28ENG%29 website)	PU
27/05	Gimv : Complement Therapeutics Announces Completion of Cohort 1 Dosing and Favourable Independent Data Monitoring Committee Recommendation in the Phase I/II Opti-GAIN Study for Geographic Atrophy Secondary to AMD	PU
27/05	Gimv : Trading update	PU
22/05	Gimv : Cegeka Acquires Swiss Industry Specialist Lean Projects	PU
20/05	Gimv : TINC- Trading update over the 1Q 2026	PU
07/05	Gimv : Cegeka Closes 2025 With a Solid Foundation, Ready for Further Growth	PU
30/04	New Gimv Anchor investment: acquisition of 5% shareholding in Azelis	PU
27/04	Gimv : Convocation annual general meeting of May 27, 2026	PU
27/04	Gimv : CV directors to be (re)appointed (CV%27s bestuurders %28ENG%29)	PU
24/04	Gimv : Route description (DOC10 260527 Route description Crowne Plaza %28ENG%29)	PU
25/03	Gimv : Complement Therapeutics Announces First Patient Dosed with CTx001 in the Phase I/II Opti-GAIN Study for Geographic Atrophy Secondary to AMD	PU
24/03	Gimv : secures new EUR 400 million revolving credit facility to support accelerated growth ambitions	PU
11/03	Gimv : BioConnection is proud to announce its latest investment in further growth	PU